Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 18/20 | 0.76 |
| ▸ | HTR6 | P50406 | 18/20 | 0.76 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.71 |
| ▸ | HTR2A | P28223 | 3/20 | 0.71 |
| ▸ | HTR2C | P28335 | 3/20 | 0.71 |
| ▸ | HTR7 | P34969 | 3/20 | 0.71 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.71 |
| ▸ | DRD2 | P14416 | 2/20 | 0.69 |
| ▸ | BCHE | P06276 | 1/20 | 0.68 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.68 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.68 |
| ▸ | ACHE | P22303 | 1/20 | 0.68 |
| ▸ | HRH2 | P25021 | 1/20 | 0.68 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.68 |
| ▸ | HTR1D | P28221 | 1/20 | 0.68 |
| ▸ | HTR1E | P28566 | 1/20 | 0.68 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.68 |
| ▸ | DRD3 | P35462 | 1/20 | 0.68 |
| ▸ | HTR2B | P41595 | 1/20 | 0.68 |
| ▸ | HTR5A | P47898 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1905784 | 0.92 | HRH1 (0.78) | HRH1HTR6ADRA2AHTR2AHTR2C | |
| SCHEMBL3719294 | 0.91 | HRH1 (0.77) | HRH1HTR6ADRA2AHTR2AHTR2C | |
| SCHEMBL1905330 | 0.89 | HRH1 (0.60) | HRH1HTR6ADRA2AHTR2AHTR2C | |
| SCHEMBL1907947 | 0.89 | HRH1 (0.60) | HRH1HTR6ADRA2AHTR2AHTR2C | |
| SCHEMBL1907819 | 0.89 | HRH1 (0.65) | HRH1HTR6ADRA2AHTR2AHTR2C | |
| SCHEMBL1905002 | 0.89 | HRH1 (0.65) | HRH1HTR6ADRA2AHTR2AHTR2C | |
| SCHEMBL1908053 | 0.89 | HTR6 (0.66) | HRH1HTR6ADRA2AHTR2AHTR2C | |
| SCHEMBL1903494 | 0.89 | HTR6 (0.71) | HRH1HTR6ADRA2AHTR2AHTR2C | |
| SCHEMBL1908111 | 0.88 | HRH1 (0.59) | HRH1HTR6ADRA2AHTR2AHTR2C | |
| SCHEMBL4127975 | 0.88 | HRH1 (0.73) | HRH1HTR6ADRA2AHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105912-A1 | FLUORO-CONTAINING DERIVATIVES OF HYDROGENATED PYRIDO[4,3-b]INDOLES WITH NEUROPROTECTIVE AND COGNITION ENHANCING PROPERTIES, PROCESS FOR PREPARING, AND USE | D2E, LLC (US) | 2010-04-29 | — | — | US | claimed |
| US-20100056790-A1 | FLUORO-CONTAINING DERIVATIVES OF HYDROGENATED PYRIDO[4,3-B]INDOLES WITH NEUROPROTECTIVE AND COGNITION ENHANCING PROPERTIES, PROCESS FOR PREPARING, AND USE | D2E, LLC (US) | 2010-03-04 | — | — | US | claimed |
| US-20090221627-A1 | Fluoro-containing derivatives of hydrogenated pyrido[4,3-b]indoles with neuroprotective and cognition enhancing properties, process for preparing, and use | D2E, LLC | 2009-09-03 | — | — | US | claimed |
| US-9550782-B2 | Compounds and methods for treating diabetes | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550782-B2 | Compounds and methods for treating diabetes | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550782-B2 | Compounds and methods for treating diabetes | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9527854-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527854-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527854-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9181240-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9181240-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20100056790-A1 | FLUORO-CONTAINING DERIVATIVES OF HYDROGENATED PYRIDO[4,3-B]INDOLES WITH NEUROPROTECTIVE AND COGNITION ENHANCING PROPERTIES, PROCESS FOR PREPARING, AND USE | D2E, LLC (US) | 2010-03-04 | — | — | US | disclosed |
| US-20090239854-A1 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. | 2009-09-24 | — | — | US | disclosed |
| US-20090239854-A1 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. | 2009-09-24 | — | — | US | disclosed |
| US-20090239854-A1 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. | 2009-09-24 | — | — | US | disclosed |
| US-20090221627-A1 | Fluoro-containing derivatives of hydrogenated pyrido[4,3-b]indoles with neuroprotective and cognition enhancing properties, process for preparing, and use | D2E, LLC | 2009-09-03 | — | — | US | disclosed |
| US-20090221627-A1 | Fluoro-containing derivatives of hydrogenated pyrido[4,3-b]indoles with neuroprotective and cognition enhancing properties, process for preparing, and use | D2E, LLC | 2009-09-03 | — | — | US | disclosed |
| US-20090221627-A1 | Fluoro-containing derivatives of hydrogenated pyrido[4,3-b]indoles with neuroprotective and cognition enhancing properties, process for preparing, and use | D2E, LLC | 2009-09-03 | — | — | US | disclosed |
| WO-2009055828-A1 | NEW TETRACYCLIC COMPOUNDS | MEDIVATION TECHNOLOGIES, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009038764-A1 | FLUORO-CONTAINING DERIVATIVES OF HYDROGENTED PYRIDO[4,3-B]INDOLES WITH NEUROPROTECTIVE AND COGNITION ENHANCING PROPERTIES, PROCESS FOR PREPARING, AND USE | D2E, LLC (US) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221627-A1 | Fluoro-containing derivatives of hydrogenated pyrido[4,3-b]indoles with neuroprotective and cognition enhancing properties, process for preparing, and use | HTR4, SNCA, HTR2B | HRH1 1357/4885HTR6 8/4885ADRA2A 493/4885 |
| US-20100105912-A1 | FLUORO-CONTAINING DERIVATIVES OF HYDROGENATED PYRIDO[4,3-b]INDOLES WITH NEUROPROTECTIVE AND COGNITION ENHANCING PROPERTIES, PROCESS FOR PREPARING, AND USE | HTR4, SNCA, HTR2B | HRH1 1357/4885HTR6 8/4885ADRA2A 493/4885 |
| US-20090239854-A1 | Tetracyclic compounds | HTR2C, HTR3D, HTR5A | HRH1 31/4885HTR6 10/4885ADRA2A 200/4885 |
| US-20100056790-A1 | FLUORO-CONTAINING DERIVATIVES OF HYDROGENATED PYRIDO[4,3-B]INDOLES WITH NEUROPROTECTIVE AND COGNITION ENHANCING PROPERTIES, PROCESS FOR PREPARING, AND USE | HTR4, SNCA, HTR2B | HRH1 1357/4885HTR6 8/4885ADRA2A 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.